What is essential thrombocythemia (ET)?
Essential thrombocythemia (also called ET) is a chronic blood cancer in which the bone marrow makes too many platelets, the blood cells that help your blood clot and stop bleeding. It is part of a group of conditions called myeloproliferative neoplasms (MPNs), which also include polycythemia vera and myelofibrosis.
In ET, the extra platelets can make the blood “thicker” and increase the risk of blood clots or, less often, bleeding problems. Many people live with ET for decades, and treatment focuses on lowering clot risk and managing symptoms.
How is ET usually found and diagnosed?
ET is often picked up on a routine blood test that shows a high platelet count (typically above 450,000 per microliter) when you may feel well. To confirm the diagnosis, your doctor may order repeat blood counts, a bone marrow biopsy, and genetic tests that look for common mutations such as JAK2, CALR, or MPL.
Doctors also rule out other causes of a high platelet count, such as infection, inflammation, iron deficiency, or another blood disease. Once those are excluded and ET features are present, your team can confirm ET and begin to discuss your risk level and treatment plan.
What symptoms should I watch for?
Some people with ET have no symptoms at all and only learn about the condition after an abnormal blood test. Others may notice headaches, dizziness, changes in vision, ringing in the ears, burning pain or redness in the hands and feet, or unusual tiredness.
Because ET affects clotting, you may also see easy bruising, nosebleeds, bleeding from gums, heavy menstrual periods, or, less often, signs of serious clots such as chest pain, trouble speaking, weakness on one side, or sudden leg swelling. Report any new or worsening symptoms to your care team right away so they can decide whether urgent evaluation is needed.
How serious is ET?
ET is serious because of the risk of blood clots and, more rarely, bleeding or progression to other blood cancers, but many people live a near‑normal life span with good monitoring and treatment.
A small percentage of patients may eventually develop myelofibrosis (scarring of the bone marrow) or acute myeloid leukemia, which are more aggressive conditions. Your team will follow your blood counts, symptoms, and sometimes your spleen size over time to watch for any signs of change.
What are the main risks doctors worry about?
The main concern in ET is blood clots, which can occur in arteries (leading to heart attack or stroke) or veins (such as clots in the legs or lungs). Less commonly, very high platelet counts or certain treatments can raise the risk of bleeding problems.
Doctors also pay attention to long‑term risks like progression to myelofibrosis or acute leukemia, though this happens in only a minority of patients. Cardiovascular risk factors—such as smoking, high blood pressure, high cholesterol, diabetes, and obesity—can add to clot risk, so managing these is an important part of care.
How do doctors decide my risk level?
Your care team looks at several features to estimate your risk of clots and guide treatment. Key factors include your age, whether you have ever had a blood clot, whether you have the JAK2 mutation, how high your platelet count is, and other cardiovascular conditions such as smoking, high blood pressure, or diabetes.
Commonly, people are grouped into very low, low, intermediate, or high‑risk categories based on age, clot history, and JAK2 status. This risk level helps determine whether you need aspirin alone, aspirin plus medication to lower platelets, or more intensive treatment.
What treatments are available for ET?
The main goal of ET treatment is to lower the chance of blood clots and bleeding while controlling symptoms. Many patients take low‑dose aspirin to make platelets less “sticky” and to ease microvascular symptoms such as headaches or redness and burning in the hands and feet.
People at higher risk may also receive cytoreductive (platelet‑lowering) medicines such as hydroxyurea or pegylated interferon‑alpha; other drugs like busulfan may be used if first‑line options are not suitable. In rare situations with extremely high platelets or emergency clots, a procedure called plateletpheresis can quickly lower platelet counts.
Will I always need treatment, or can I just be monitored?
Not everyone with ET needs medicine right away; some people with very low clot risk are monitored with regular checks and may only take low‑dose aspirin. Others, especially those who are older, have a history of clots, or have very high platelet counts, are more likely to benefit from platelet‑lowering treatment in addition to aspirin.
Your treatment plan can change over time as you age, your blood counts change, or new symptoms appear. Regular follow‑up visits and blood tests allow your team to adjust your medicines to keep you as safe and well as possible.
What side effects should I know about from common ET treatments?
Low‑dose aspirin can irritate the stomach and increase the risk of bleeding, including nosebleeds, bruising, or bleeding in the digestive tract, especially at higher doses. Hydroxyurea may cause fatigue, mild nausea, skin or nail changes, and lowered white blood cells or red blood cells, so blood counts are checked regularly.
Pegylated interferon‑alpha can cause flu‑like symptoms, mood changes, or liver test abnormalities in some people. Every medicine has potential risks and benefits, so talk with your team about what to watch for and when to call.
How often will I need blood tests and doctor visits?
Because ET is a lifelong condition, you can expect regular appointments and lab work. Early on, visits may be more frequent to fine‑tune your treatment; over time, many people move to every few months if their counts and symptoms are stable.
At each visit, your doctor will review your symptoms, check for an enlarged spleen, and order blood tests to look at your platelet count, red and white blood cells, and sometimes iron levels or other labs. Keeping your appointments and having labs done as scheduled is one of the best ways to stay ahead of problems.
Can ET turn into myelofibrosis or leukemia?
ET can sometimes change over many years into myelofibrosis, where scar tissue builds up in the bone marrow and can cause anemia, fatigue, night sweats, weight loss, or a very enlarged spleen. In a smaller number of patients, ET may transform into acute myeloid leukemia, a fast‑growing blood cancer that requires different treatment.
These complications are not common, and most people with ET will never experience them. Regular monitoring helps your team spot early signs of change and discuss testing or treatment options if needed.
What lifestyle changes can help lower my risk?
Healthy lifestyle choices are an important part of ET care and can help reduce your risk of clots. Steps that often help include not smoking, keeping blood pressure and cholesterol under control, managing diabetes, staying physically active, and maintaining a healthy weight.
Your doctor may also encourage you to stay well hydrated, especially on hot days or when traveling, and to avoid long periods of sitting without moving your legs. Work with your team to create an activity and wellness plan that fits your abilities and other medical conditions.
Is it safe to get pregnant if I have ET?
Many women with ET have healthy pregnancies, but ET does increase the risk of complications such as miscarriage, pre‑eclampsia, and blood clots, so pregnancy needs special planning. Some ET medicines are not safe in pregnancy and may need to be stopped or changed before you try to conceive.
If you are thinking about pregnancy, ask for a pre‑pregnancy consultation with a hematologist and a high‑risk obstetrician experienced in caring for women with blood disorders. Together, they can adjust your medicines, plan close monitoring, and discuss how to manage labor, delivery, and the period after birth.
How might ET affect surgery, dental work, or other procedures?
Because ET affects blood clotting, it is important to tell surgeons, dentists, and other providers about your diagnosis and medicines well before any planned procedure. Your hematologist may recommend adjusting aspirin or platelet‑lowering drugs, or taking other steps around the time of surgery to balance bleeding and clotting risks.
For emergency procedures, your hospital team may consult a hematologist to help manage your ET during and after surgery. Ask your regular ET doctor if you should carry a wallet card or patient summary that explains your diagnosis and current treatment.
Should I consider joining a clinical trial?
Clinical trials test new ways to treat or monitor ET and related MPNs and may offer access to promising therapies that are not yet widely available. Trials can look at new drugs, new combinations of existing medicines, or better ways to predict who is at higher risk of progression.
Not everyone needs or wants a clinical trial, but it can be useful to ask your hematologist if there are any studies that fit your situation, either now or in the future. Patient advocacy groups and academic centers often list open MPN trials on their websites.
How can I cope emotionally with an ET diagnosis?
Living with a chronic blood cancer can bring feelings of worry, sadness, anger, or uncertainty, even if you feel physically well. Many people find it helpful to learn about ET from reliable sources, bring written questions to visits, and involve a trusted family member or friend in appointments.
Support groups (online or in person), counseling, and peer‑to‑peer programs for people with MPNs can also be valuable. Let your care team know if you feel overwhelmed, depressed, or anxious—they can connect you with social workers, psychologists, or other resources who understand what it is like to live with ET.
Where can I find reliable information and support?
Several organizations provide education and support for people living with ET and other MPNs, including patient advocacy groups, academic cancer centers, and national guidelines written for patients. These resources may offer booklets, videos, webinars, checklists for doctor visits, and ways to connect with others who share your diagnosis.
Join the conversation on CancerConnect to share your experience, ask a question and connect with others living with ET. CancerConnect has been supporting, empowering, and connecting patients and caregivers since 1997. CancerConnect combines a moderated community, daily cancer news, and educational resources.
This “Ask the Expert” FAQ is for education only and is not a substitute for medical advice. Always discuss your own situation, test results, and treatment options with your healthcare team.
More Reading
Overview of Myeloproliferative Neoplasms
Overview of Essential Thrombocythemia
Myeloproliferative Neoplasms and Fatigue
Depression Is Not “Just in Your Head”: Spotting and Treating Hidden Mood Changes in MPNs
